Clinical Report: Evaluating CHA2DS2-VA and Non-CHA2DS2-VA Factors as Indicators of Mortality Following Cavotricuspid Isthmus Ablation

Overview

This study evaluates the CHA₂DS₂-VA score and non-CHA₂DS₂-VA comorbidities as predictors of all-cause mortality after cavotricuspid isthmus (CTI) ablation for typical atrial flutter (AFL).

Background

Typical atrial flutter (AFL) is a common cardiac arrhythmia associated with significant morbidity and mortality. While CTI ablation is an effective treatment, long-term outcomes can vary based on individual risk factors.

Data Highlights

Key Findings

• 27% of patients died during a mean follow-up of 1771 ± 635 days.
• Mortality increased with higher CHA₂DS₂-VA scores (log-rank p < 0.001).
• A CHA₂DS₂-VA score ≥3 was identified as the optimal threshold for mortality prediction.
• The CHA₂DS₂-VA score showed good discriminative ability (c-index = 0.73).
• Pulmonary disease and obstructive sleep apnoea were independent predictors of long-term survival.
• Female sex was not significantly associated with mortality.

Clinical Implications

The CHA₂DS₂-VA score can be an independent predictor of long-term mortality following CTI ablation for AFL.

Conclusion

The CHA₂DS₂-VA score serves as a predictor of all-cause mortality after CTI ablation for typical AFL.

Related Resources & Content

1. Frontiers in Cardiovascular Medicine, 2026 -- CHA2DS2-VA score for predicting ventricular arrhythmias and mortality in ICD patients with ischemic heart disease and dilated cardiomyopathy: results from a prospective cohort
2. Clinical Research in Cardiology, 2023 -- Cardio-hepatic syndrome in individuals receiving transcatheter aortic valve replacement therapy
3. Clinical Research in Cardiology, 2018 -- The Relationship Between Inflammation and Atrial High-Rate Episodes in Patients with Cardiac Implantable Devices
4. Clinical Research in Cardiology, 2025 -- Assessment of Patient Risk Factors for Transcatheter Aortic Valve Replacement (PRE-TAVR) -- Identifying Predictors of Short- and Long-Term Mortality in Real Time
5. Management of patients with atrial tachycardia: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), and the Association for European Paediatric and Congenital Cardiology (AEPC) - PMC
6. Frontiers, 2025 -- Acute and long-term procedural outcomes, arrhythmia recurrence and mortality after supraventricular arrhythmia ablation: a comparative study of fluoroscopy and zero-fluoroscopy guided techniques
7. PubMed -- CHADS2 and CHA2DS2-VASc scores as tools for long-term mortality prognosis in patients with typical atrial flutter after catheter ablation
8. Management of patients with atrial tachycardia: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), and the Association for European Paediatric and Congenital Cardiology (AEPC) - PMC
9. Frontiers | Acute and long-term procedural outcomes, arrhythmia recurrence and mortality after supraventricular arrhythmia ablation: a comparative study of fluoroscopy and zero-fluoroscopy guided techniques
10. CHADS2 and CHA2DS2-VASc scores as tools for long-term mortality prognosis in patients with typical atrial flutter after catheter ablation - PubMed